Complete replication of hepatitis C virus in cell culture
- PMID: 15947137
- DOI: 10.1126/science.1114016
Complete replication of hepatitis C virus in cell culture
Abstract
Many aspects of the hepatitis C virus (HCV) life cycle have not been reproduced in cell culture, which has slowed research progress on this important human pathogen. Here, we describe a full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc). Replication of HCVcc was robust, producing nearly 10(5) infectious units per milliliter within 48 hours. Virus particles were filterable and neutralized with a monoclonal antibody against the viral glycoprotein E2. Viral entry was dependent on cellular expression of a putative HCV receptor, CD81. HCVcc replication was inhibited by interferon-alpha and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals.
Similar articles
-
Construction of the Vero cell culture system that can produce infectious HCV particles.Mol Biol Rep. 2009 Jan;36(1):111-20. doi: 10.1007/s11033-007-9158-3. Epub 2007 Oct 25. Mol Biol Rep. 2009. PMID: 17960493
-
Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins.Biochem Biophys Res Commun. 2008 Jul 4;371(3):446-50. doi: 10.1016/j.bbrc.2008.04.110. Epub 2008 Apr 28. Biochem Biophys Res Commun. 2008. PMID: 18445476
-
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.J Virol. 2007 Jan;81(2):1043-7. doi: 10.1128/JVI.01710-06. Epub 2006 Nov 1. J Virol. 2007. PMID: 17079294 Free PMC article.
-
Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.Antiviral Res. 2018 Oct;158:264-287. doi: 10.1016/j.antiviral.2018.07.014. Epub 2018 Jul 27. Antiviral Res. 2018. PMID: 30059723 Review.
-
Replication of the hepatitis C virus in cell culture.Antiviral Res. 2003 Oct;60(2):91-102. doi: 10.1016/j.antiviral.2003.08.016. Antiviral Res. 2003. PMID: 14638404 Review.
Cited by
-
Development of reverse genetics for Ibaraki virus to produce viable VP6-tagged IBAV.FEBS Open Bio. 2015 May 27;5:445-53. doi: 10.1016/j.fob.2015.05.006. eCollection 2015. FEBS Open Bio. 2015. PMID: 26101741 Free PMC article.
-
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1101-10. doi: 10.1073/pnas.1203829109. Epub 2012 Mar 30. Proc Natl Acad Sci U S A. 2012. PMID: 22467829 Free PMC article.
-
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.PLoS One. 2013;8(3):e59776. doi: 10.1371/journal.pone.0059776. Epub 2013 Mar 19. PLoS One. 2013. PMID: 23527266 Free PMC article.
-
Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.J Virol. 2016 Nov 14;90(23):10486-10498. doi: 10.1128/JVI.01462-16. Print 2016 Dec 1. J Virol. 2016. PMID: 27630242 Free PMC article.
-
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10. doi: 10.1073/pnas.1114927109. Epub 2012 Apr 4. Proc Natl Acad Sci U S A. 2012. PMID: 22492964 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources

